杨森-话题@MedSci

#杨森#

40篇内容 | 1165人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2126336, encodeId=67fd2126336cc, content=好奇<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a> <a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a><a href='/topic/show?id=d61a9261957' target=_blank style='color:#2F92EE;'>#赛诺菲#</a><a href='/topic/show?id=e0df9e832a7' target=_blank style='color:#2F92EE;'>#阿斯利康#</a><a href='/topic/show?id=4c2ce960918' target=_blank style='color:#2F92EE;'>#罗氏#</a><a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>这些大公司在中国的知名度，看看它们的围观人数，是不是成正比！, objectTitle=辉瑞, objectType=topic, longId=93725, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=1, likeNumber=53, createdTime=2023-04-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=香港, moduleDTOList=null, followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1543234, encodeId=10741543234bc, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森前高管樊杰赴任梅斯医学CEO, objectType=article, longId=299923, objectId=939729992364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=939729992364, replyNumber=0, likeNumber=38, createdTime=2022-03-04, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=939729992364, moduleTitle=西安杨森前高管樊杰赴任梅斯医学CEO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=939729992364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543233, encodeId=d5f715432332b, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=第二十二届吴阶平-保罗·杨森医学药学奖揭晓, objectType=article, longId=295289, objectId=f806295289ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f806295289ad, replyNumber=0, likeNumber=37, createdTime=2022-02-10, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f806295289ad, moduleTitle=第二十二届吴阶平-保罗·杨森医学药学奖揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f806295289ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543230, encodeId=35541543230d5, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=梅斯医学与西安杨森爱可泰隆签署战略合作，共同推动罕见病领域认知与诊疗水平, objectType=article, longId=220573, objectId=60602205e3e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60602205e3e4, replyNumber=0, likeNumber=43, createdTime=2021-11-20, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60602205e3e4, moduleTitle=梅斯医学与西安杨森爱可泰隆签署战略合作，共同推动罕见病领域认知与诊疗水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60602205e3e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543231, encodeId=40731543231df, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森中国又有4个创新药被纳入国家医保目录，6个产品成功续约, objectType=article, longId=217202, objectId=c93d21e20202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c93d21e20202, replyNumber=0, likeNumber=29, createdTime=2021-09-18, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c93d21e20202, moduleTitle=杨森中国又有4个创新药被纳入国家医保目录，6个产品成功续约, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c93d21e20202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543232, encodeId=ac22154323248, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森制药聚焦数据科学，助力中国药物和医疗创新, objectType=article, longId=216576, objectId=7b9a2165e622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b9a2165e622, replyNumber=0, likeNumber=37, createdTime=2021-09-03, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b9a2165e622, moduleTitle=杨森制药聚焦数据科学，助力中国药物和医疗创新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b9a2165e622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543229, encodeId=4328154322998, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=实践前腺专题-加强指南宣讲，促进规范诊疗-西安杨森, objectType=article, longId=216414, objectId=ed0a216414f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed0a216414f3, replyNumber=0, likeNumber=0, createdTime=2021-08-30, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed0a216414f3, moduleTitle=实践前腺专题-加强指南宣讲，促进规范诊疗-西安杨森, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed0a216414f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543228, encodeId=17ad154322853, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=JAMA: 阿斯利康、杨森/强生COVID-19疫苗引起脑静脉窦血栓形成和血小板减少又添新佐证, objectType=article, longId=215031, objectId=ced7215031a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced7215031a6, replyNumber=0, likeNumber=42, createdTime=2021-07-31, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced7215031a6, moduleTitle=JAMA: 阿斯利康、杨森/强生COVID-19疫苗引起脑静脉窦血栓形成和血小板减少又添新佐证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced7215031a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543227, encodeId=d129154322ede, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, objectType=article, longId=192695, objectId=249d19269580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=249d19269580, replyNumber=0, likeNumber=39, createdTime=2020-04-23, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=249d19269580, moduleTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=249d19269580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543226, encodeId=265d1543226b4, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=XBiotech将Bermekimab出售给杨森, objectType=article, longId=185515, objectId=11a218551526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a218551526, replyNumber=0, likeNumber=29, createdTime=2020-01-02, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a218551526, moduleTitle=XBiotech将Bermekimab出售给杨森, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a218551526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543225, encodeId=c5eb154322528, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, objectType=article, longId=185462, objectId=7bae18546288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bae18546288, replyNumber=0, likeNumber=34, createdTime=2020-01-01, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bae18546288, moduleTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bae18546288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543224, encodeId=0c1815432249c, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批, objectType=article, longId=183746, objectId=ed7f183e4699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed7f183e4699, replyNumber=0, likeNumber=46, createdTime=2019-11-30, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed7f183e4699, moduleTitle=西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7f183e4699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543223, encodeId=18201543223c7, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市, objectType=article, longId=183710, objectId=6798183e1036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6798183e1036, replyNumber=0, likeNumber=57, createdTime=2019-11-29, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6798183e1036, moduleTitle=西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6798183e1036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543222, encodeId=79b41543222b2, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森宣布全球CD38单克隆抗体靶向药物兆珂(R)在中国上市, objectType=article, longId=181322, objectId=2ee818132282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ee818132282, replyNumber=0, likeNumber=46, createdTime=2019-10-17, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ee818132282, moduleTitle=西安杨森宣布全球CD38单克隆抗体靶向药物兆珂(R)在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ee818132282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543221, encodeId=4629154322136, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=全新作用机制开创骨髓瘤治疗新时代西安杨森宣布全球CD38单克隆抗体靶向药物兆珂®在中国上市, objectType=article, longId=181286, objectId=6a1418128699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1418128699, replyNumber=0, likeNumber=0, createdTime=2019-10-17, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1418128699, moduleTitle=全新作用机制开创骨髓瘤治疗新时代西安杨森宣布全球CD38单克隆抗体靶向药物兆珂®在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1418128699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543220, encodeId=ddae154322031, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=世界精神卫生日西安杨森呼吁全社会接纳精神障碍患者, objectType=article, longId=180939, objectId=9c6318093902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c6318093902, replyNumber=0, likeNumber=42, createdTime=2019-10-12, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c6318093902, moduleTitle=世界精神卫生日西安杨森呼吁全社会接纳精神障碍患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c6318093902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543219, encodeId=99b5154321937, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森宣布国内每三月皮下注射一次治疗银屑病生物制剂喜达诺®上市, objectType=article, longId=167787, objectId=f96e16e787c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96e16e787c7, replyNumber=0, likeNumber=42, createdTime=2019-06-08, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96e16e787c7, moduleTitle=西安杨森宣布国内每三月皮下注射一次治疗银屑病生物制剂喜达诺®上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96e16e787c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543218, encodeId=050c15432183d, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森旗下类克为中国溃疡性结肠炎提供生物制剂新选择, objectType=article, longId=160429, objectId=fcac16042929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcac16042929, replyNumber=0, likeNumber=44, createdTime=2019-02-20, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcac16042929, moduleTitle=西安杨森旗下类克为中国溃疡性结肠炎提供生物制剂新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcac16042929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543217, encodeId=89c9154321ef4, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森两款艾滋病创新药物恩临和普泽力宣布在华上市, objectType=article, longId=154280, objectId=28011542800a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28011542800a, replyNumber=0, likeNumber=52, createdTime=2018-11-25, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28011542800a, moduleTitle=西安杨森两款艾滋病创新药物恩临和普泽力宣布在华上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28011542800a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543216, encodeId=c93c15432160b, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=美国强生旗下西安杨森总裁：中国正从制药大国向创新大国改变, objectType=article, longId=152754, objectId=31a7152e5491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a7152e5491, replyNumber=0, likeNumber=30, createdTime=2018-11-06, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a7152e5491, moduleTitle=美国强生旗下西安杨森总裁：中国正从制药大国向创新大国改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31a7152e5491)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

(审核中...)

前往app查看评论内容

好奇#辉瑞# #诺华##赛诺菲##阿斯利康##罗氏##杨森#这些大公司在中国的知名度，看看它们的围观人数，是不是成正比！

2023-04-16发表于香港

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森前高管樊杰赴任梅斯医学CEO

2022-03-04

陆成振 (审核中...)

前往app查看评论内容

#杨森#

第二十二届吴阶平-保罗·杨森医学药学奖揭晓

2022-02-10

陆成振 (审核中...)

前往app查看评论内容

#杨森#

梅斯医学与西安杨森爱可泰隆签署战略合作，共同推动罕见病领域认知与诊疗水平

2021-11-20

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森中国又有4个创新药被纳入国家医保目录，6个产品成功续约

2021-09-18

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森制药聚焦数据科学，助力中国药物和医疗创新

2021-09-03

陆成振 (审核中...)

前往app查看评论内容

#杨森#

实践前腺专题-加强指南宣讲，促进规范诊疗-西安杨森

2021-08-30

陆成振 (审核中...)

前往app查看评论内容

#杨森#

JAMA: 阿斯利康、杨森/强生COVID-19疫苗引起脑静脉窦血栓形成和血小板减少又添新佐证

2021-07-31

陆成振 (审核中...)

前往app查看评论内容

#杨森#

斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！

2020-04-23

陆成振 (审核中...)

前往app查看评论内容

#杨森#

XBiotech将Bermekimab出售给杨森

2020-01-02

陆成振 (审核中...)

前往app查看评论内容

#杨森#

银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批

2020-01-01

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批

2019-11-30

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市

2019-11-29

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森宣布全球CD38单克隆抗体靶向药物兆珂(R)在中国上市

2019-10-17

陆成振 (审核中...)

前往app查看评论内容

#杨森#

全新作用机制开创骨髓瘤治疗新时代西安杨森宣布全球CD38单克隆抗体靶向药物兆珂®在中国上市

2019-10-17

陆成振 (审核中...)

前往app查看评论内容

#杨森#

世界精神卫生日西安杨森呼吁全社会接纳精神障碍患者

2019-10-12

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森宣布国内每三月皮下注射一次治疗银屑病生物制剂喜达诺®上市

2019-06-08

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森旗下类克为中国溃疡性结肠炎提供生物制剂新选择

2019-02-20

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森两款艾滋病创新药物恩临和普泽力宣布在华上市

2018-11-25

陆成振 (审核中...)

前往app查看评论内容

#杨森#

美国强生旗下西安杨森总裁：中国正从制药大国向创新大国改变

2018-11-06

科室
- - 订阅+
  - 更多科室
工具
服务